Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest.
Chemoprevention of colorectal cancer using aspirin has been demonstrated in rodents and has been suggested by data from epidemiological studies. The mechanism that accounts for this prevention is unknown, but it is thought to relate to an irreversible inhibition of cyclooxygenase and, subsequently, prostaglandin production. The effect of aspirin on the growth of human colonic tumor cells was determined in an effort to gain insight into a possible mechanism of action. In the two cell lines studied, SW 620 and HT-29, we observed a significant dose- and time-dependent increase in aspirin toxicity in a concentration range of 1.25-10 mM. This result was independent of prostaglandin production, because there was no measurable prostaglandin E2 in cell culture medium. As compared with controls, cells in cultures that contained aspirin were not detached, which suggests that the mechanism of cell death was not apoptosis. Flow cytometric analysis revealed an increase in S phase and G2-M populations as well as the number of subdiploid nuclei in cultures treated with high-dose aspirin. Confirmation that cells were undergoing necrosis in response to aspirin was evident from the presence of cells that bound annexin V and accumulated propidium iodide in the absence of a population that bound annexin alone. The results suggest that aspirin induces cell cycle arrest and causes necrosis at high concentrations in vitro, but does not induce apoptosis. Collectively, these two events, necrosis and cell cycle arrest, may contribute to the chemopreventive effect that seems to result from long-term administration of aspirin in vivo.
Subbegowda
R
R
Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Frommel
T O
TO
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000187:drug effects; D015232:Dinoprostone / Q000032:analysis; D005434:Flow Cytometry; D019073:HT29 Cells / Q000187:drug effects; D006801:Humans; D009336:Necrosis; D009363:Neoplasm Proteins / Q000032:analysis; D014747:Vinblastine / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D016861:Cyclooxygenase Inhibitors; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D014747:Vinblastine; D015232:Dinoprostone; D001241:Aspirin